Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1B | O75688 | 2/20 | 0.62 |
| ▸ | PPM1A | P35813 | 2/20 | 0.59 |
| ▸ | ALPI | P09923 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | XIAP | P98170 | 1/20 | 0.41 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | SLC15A1 | P46059 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | SRR | Q9GZT4 | 2/20 | 0.36 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.36 |
| ▸ | LAP3 | P28838 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4315586 | 1.00 | PPM1B (0.62) | PPM1BPPM1AALPIPKMPTGS1 | |
| SCHEMBL4315591 | 1.00 | PPM1B (0.62) | PPM1BPPM1AALPIPKMPTGS1 | |
| SCHEMBL4315593 | 1.00 | PPM1B (0.62) | PPM1BPPM1AALPIPKMPTGS1 | |
| SCHEMBL27858195 | 0.75 | CYP1A2 (0.50) | PPM1BALPIPKMPTGS1XIAP | |
| SCHEMBL20576648 | 0.73 | PPM1B (0.41) | PPM1BPPM1AALPIPKMPTGS1 | |
| SCHEMBL31106393 | 0.71 | TRPA1 (0.51) | PPM1BALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1695172 | 0.67 | SLC1A3 (0.49) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL4992286 | 0.67 | ACE (0.42) | PPM1BALPIPKMPTGS1XIAP | |
| SCHEMBL8561050 | 0.66 | ALPI (0.60) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL17905254 | 0.65 | MEN1 (0.46) | ALPIPKMPTGS1XIAPSLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275885-A1 | Microcystins as agents for treatment of cancer | UNIVERSITY OF KENTUCKY (US) | 2007-11-29 | — | — | US | claimed |
| US-20250082595-A1 | METHODS AND COMPOSITIONS FOR TREATING PARKINSON’S DISEASE | NEURODERM LTD (IL) | 2025-03-13 | — | — | US | disclosed |
| US-20240315997-A1 | METHOD OF TREATMENT OF PARKINSON’S DISEASE | NEURODERM, LTD. (IL) | 2024-09-26 | — | — | US | disclosed |
| US-11844754-B2 | Methods for treatment of Parkinson's disease | NEURODERM, LTD. (IL) | 2023-12-19 | — | — | US | disclosed |
| WO-2023209055-A1 | CALPROTECTIN BINDING PEPTIDES | BÜHLMANN LABORATORIES AG (CH) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023164003-A2 | REAGENTS FOR LABELING BIOMOLECULES AND USES THEREOF | ULTIMA GENOMICS, INC. (US) | 2023-08-31 | — | — | WO | disclosed |
| WO-2023126945-A1 | METHODS AND COMPOSITIONS FOR TREATING PARKINSON'S DISEASE | NEURODERM, LTD. (IL) | 2023-07-06 | — | — | WO | disclosed |
| US-20230157985-A1 | METHODS FOR TREATMENT OF PARKINSON'S DISEASE | NEURODERM, LTD. (IL) | 2023-05-25 | — | — | US | disclosed |
| US-11512114-B2 | Modified microcystins and nodularins | CYANO BIOTECH GMBH (DE) | 2022-11-29 | — | — | US | disclosed |
| US-20220362386-A1 | LIQUID COMPOSITIONS COMPRISING A LEVODOPA AMINO ACID CONJUGATE AND USES THEREOF | NEURODERM LTD (IL) | 2022-11-17 | — | — | US | disclosed |
| WO-2018206715-A2 | MODIFIED MICROCYSTINS AND NODULARINS | CYANO BIOTECH GMBH (DE) | 2018-11-15 | — | — | WO | disclosed |
| US-20180321237-A1 | Protocol for Preconcentration and Quantification of Microcystins Using LC-MS | THE UNIVERSITY OF TOLEDO (US) | 2018-11-08 | — | — | US | disclosed |
| US-20180127293-A1 | CHLORINATION-UV PROCESS FOR DECOMPOSITION AND DETOXIFICATION OF MICROCYSTIN-LR | PURDUE RESEARCH FOUNDATION | 2018-05-10 | — | — | US | disclosed |
| WO-2018071954-A1 | RECOMBINANT MICROCYSTIN PRODUCTION | NEWSOUTH INNOVATIONS PTY LIMITED (AU) | 2018-04-26 | — | — | WO | disclosed |
| US-9006173-B2 | Microcystins as agents for treatment of cancer | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2015-04-14 | — | — | US | disclosed |
| EP-2313776-B1 | IMMUNOASSAY FOR DETECTION OF NEUROTOXIC AMINO ACID ASSOCIATED WITH NEUROLOGICAL DISORDERS | INST ETHNOMEDICINE (US) | 2013-10-30 | — | — | EP | disclosed |
| US-20070275885-A1 | Microcystins as agents for treatment of cancer | UNIVERSITY OF KENTUCKY (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070059699-A1 | Methods for detecting toxic and non-toxic cyanobacteria | SIVONEN KAARINA | 2007-03-15 | — | — | US | disclosed |
| EP-1629114-A2 | METHOD FOR DETECTING TOXIC AND NON-TOXIC CYANOBACTERIA | Helsingin Yliopisto (FI) | 2006-03-01 | — | — | EP | disclosed |
| WO-2004104211-A2 | METHOD FOR DETECTING TOXIC AND NON-TOXIC CYANOBACTERIA | HELSINGIN YLIOPISTO (FI) | 2004-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11844754-B2 | Methods for treatment of Parkinson's disease | DDC, DDT, SLC6A3 | PPM1B 522/4885PPM1A 795/4885ALPI 228/4885 |
| US-20220362386-A1 | LIQUID COMPOSITIONS COMPRISING A LEVODOPA AMINO ACID CONJUGATE AND USES THEREOF | DAO, DDC, AADAT | PPM1B 925/4885PPM1A 607/4885ALPI 2041/4885 |
| US-20240315997-A1 | METHOD OF TREATMENT OF PARKINSON’S DISEASE | DDC, DDT, COMT | PPM1B 364/4885PPM1A 626/4885ALPI 331/4885 |
| US-20250082595-A1 | METHODS AND COMPOSITIONS FOR TREATING PARKINSON’S DISEASE | DDC, COMT, DDT | PPM1B 294/4885PPM1A 405/4885ALPI 247/4885 |
| US-20230157985-A1 | METHODS FOR TREATMENT OF PARKINSON'S DISEASE | DDC, DDT, COMT | PPM1B 540/4885PPM1A 826/4885ALPI 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.